# US 2012/0269768 A1 · Antiviral product

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269768 A1
- Document ID: US20120269768A1
- Status: Published application
- Kind: A1
- Application number: 13/525,621
- Filed: 2012-06-18
- Published: 2012-10-25
- Earliest claimed: 2006-06-16
- Inventors: Shouming Zhong; Hongwen Yu
- Web page: https://patentgrep.com/patent/US20120269768A1

## CPC

- A61K 36/481: Astragalus (milkvetch)
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a novel antiviral product, its use in the treatment of hepatitis C, and its process of manufacture. More particularly it relates to a characterised product exhibiting antiviral activity against Hepatitis C virus (HCV). In one embodiment there is provided a single herb Astragalus extract, or an active fraction thereof, for use as an antiviral in the treatment of hepatitis C.

## Claims

### Claim 1

A selective single herb Astragalus alcoholic extract characterized in that the extract of Astragalus is purified by at least a factor of 10 with reference to dried raw plant material, exhibits anti-HCV activity in a replicon assay, and comprises at least one marker selected from the group consisting of:
Astragaloside I;
Formononetin-7-O-β-D-glucoside; and
3′-hydroxyl-formononetin-7-O-β-D-glucoside.

### Claim 2 (depends on 1)

A selective single herb Astragalus alcoholic extract as claimed in claim 1 which is purified by a factor of 50 with reference to dried raw plant material.

### Claim 3 (depends on 2)

A selective single herb Astragalus alcoholic extract as claimed in claim 2 which is purified by a factor of between 75 and 200 with reference to dried raw plant material.

### Claim 4 (depends on 1)

A selective single herb Astragalus alcoholic extract as claimed in claim 1 which has been subjected to an ethanol-water precipitation process.

### Claim 5 (depends on 4)

A selective single herb Astragalus alcoholic extract as claimed in claim 4 wherein the extract has been subject to a systematic solvent fractionation step with a plurality of solvents of different polarity.

### Claim 6 (depends on 5)

A selective single herb Astragalus alcoholic extract as recited in claim 5 which is obtained from a dichloromethane fractionation or a solvent of similar polarity.

### Claim 7 (depends on 1)

A selective single herb Astragalus alcoholic extract as claimed in claim 1, wherein the single herb Astragalus alcoholic extract is from Astragalus membranaceus (Fisch) Bge. or Astragalus membranaceus Bge var. Mongholicus Hsiao.

### Claim 8 (depends on 1)

A selective single herb Astragalus alcoholic extract as claimed in claim 1 packaged or otherwise sold in a manner which indicates it is suitable and intended for use as an anti-viral to treat hepatitis C.

### Claim 9 (depends on 1)

A selective single herb Astragalus alcoholic extract as claimed in claim 1 and its use in the manufacture of a medicament for the anti viral treatment of Hepatitis C.

### Claim 10 (depends on 1)

A selective single herb Astragalus alcoholic extract as claimed in claim 1 and the use thereof in the manufacture of a food, dietary supplement or food additive for the anti viral treatment of Hepatitis C.

### Claim 11 (depends on 8)

A selective single herb Astragalus alcoholic extract as claimed in claim 8 wherein the Astragalus extract is provided in a unit dosage form.

### Claim 12 (depends on 8)

A selective single herb Astragalus alcoholic extract as claimed in claim 8 wherein the unit dosage form is for oral delivery.

### Claim 13 (depends on 8)

A selective single herb Astragalus alcoholic extract as claimed in claim 8 wherein a daily dosage is equivalent to 9 to 60 grams of raw material.

### Claim 14 (depends on 8)

A selective single herb Astragalus alcoholic extract as claimed in claim 8 wherein administration is with at least one other immuno-modulatory or anti viral drug.

### Claim 15 (depends on 14)

A selective single herb Astragalus alcoholic extract as claimed in claim 14 wherein the at least one other immuno-modulatory or anti viral drug is interferon or Ribavirin

### Claim 16

A method for producing a single herb extract of Astragalus which exhibits anti-HCV activity in a replicon assay, and which is purified by at least a factor of 10 with reference to dried raw plant material, and which is characterized in that it comprises at least one marker selected from the group consisting of:
Astragaloside I;
Formononetin-7-o-β-d-glucoside; and
3′-hydroxyl-formononetin-7-o-β-d-glucoside comprising:
a. an alcoholic extraction (which may be repeated);
b. an ethanol-water precipitation process (which may be repeated); and
c. a systematic solvent fractionation step with a plurality of solvents of different polarity.

### Claim 17 (depends on 16)

A method as claimed in claim 16 in which the alcoholic extraction is an ethanolic extraction.

### Claim 18 (depends on 16)

A method as claimed in claim 16 wherein the systematic solvent fractionation step with a plurality of solvents of different polarity comprises a dichloromethane fractionation or a fractionation with a solvent of similar polarity to dichloromethane.

### Claim 19

A selective single herb Astragalus alcoholic extract having a TLC fingerprint substantially as shown in at least one of FIG. 4, FIG. 5, and FIG. 6.
